AventaMed, a KARL STORZ Company, Receives Expanded Indication for Solo+ Tympanostomy Tube Device (TTD)
Clearance Makes Office-Based Procedure Available to a Wider Range of Patients
EL SEGUNDO, Calif., June 18, 2025--(BUSINESS WIRE)--KARL STORZ United States is proud to announce that the US Food and Drug Administration (FDA) has cleared an expanded indication for the AventaMed Solo+™ Tympanostomy Tube Device (TTD), allowing its use in pediatric patients aged 6 months and older. This expanded clearance builds on the previous 510(k) clearance, which was indicated for patients 6 to 24 months old.
The Solo+ device represents a significant advancement in pediatric ENT care. It is intended to deliver a tympanostomy tube (also known as a ventilation tube) into a patient's tympanic membrane, or eardrum, to treat problems arising from ear infections. Traditionally, this procedure would be performed in an operating room under general anesthesia. The Solo+ device offers a convenient alternative. Using as little as a topical anesthetic, the Solo+ device integrates multiple functions into a single, user-friendly instrument, deploying the tube with the press of a button. As a result, it enables tympanostomies to be performed in an office setting.
New clinical findings support the safe and effective use of the Solo+ device, showing that physicians were consistently able to complete the procedure in the office as intended—without needing to move to the operating room.
The Solo+ Tympanostomy Tube Device demonstrated consistent, reliable performance across pediatric age groups, with strong follow-up outcomes. These results provide both guardians and physicians with greater confidence in selecting an office-based approach to ear tube placement for a wider range of children.
"On behalf of patients and their families, we are excited by this expanded indication," said Chris Smith, VP of Sales & Marketing, Head & Neck Division, at KARL STORZ US. "This makes it possible to offer this effective treatment to a broad population. With clear advantages like avoiding general anesthesia, reducing total procedural costs, and delivering high patient satisfaction, the Solo+ device will benefit doctors and patients alike. It's part of our commitment to provide technology that addresses real-world needs."
About Ear Infections
Chronic ear infections are a leading reason for doctor visits among young children.1-3 Children are more susceptible to this potentially painful condition, which can adversely affect the ability to hear.1 Treatment often involves procedures known as myringotomy and tympanostomy.
Myringotomy involves making an incision in the eardrum to drain excess fluid from the middle ear. It is sometimes performed as a standalone treatment, but is often combined with tympanostomy, in which a tiny tube is inserted in the eardrum to alleviate pressure and allow fluid to drain. The procedure is common: by the age of three, nearly 1 in every 15 children will have had ear tubes.3
About KARL STORZ
Since its founding in Germany in 1945, KARL STORZ has grown to become a leading global supplier of endoscopy solutions, including imaging and integration across all sites of care. Now in its third generation, the family-owned company employs 9,400 people in more than 40 countries worldwide. The company acquired the Solo+ technology through the acquisition of AventaMed, which was spun off from Munster Technological University in 2015. For more information, visit www.karlstorz.com.
1 Ahmed S et al. Incremental health care utilization and costs for acute otitis media in children. Laryngoscope. 2014;124(1):301-5. doi: 10.1002/lary.24190.2 Bhattacharyya N, Shay SG. Epidemiology of Pediatric Tympanostomy Tube Placement in the United States. Otolaryngol Head Neck Surg. 2020;163(3):600-602. doi: 10.1177/0194599820917397.3 Rosenfeld RM et al. Clinical Practice Guideline: Tympanostomy Tubes in Children. Otolaryngol Head Neck Surg. 2013;149:S1-S35. doi: 10.1177/0194599813487302.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250618038926/en/
Contacts
Susan ManciaMobile: 562-841-1515E-mail: susan.mancia@karlstorz.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
DentalMonitoring Launches "Top Ortho Practice Award" to Recognize Data-Driven Excellence in Orthodontic Care
PARIS--(BUSINESS WIRE)--DentalMonitoring, the global leader in AI-powered remote monitoring for orthodontics, is proud to announce the launch of the Top Ortho Practice Award, the first-of-its-kind recognition program that celebrates top-performing orthodontic practices worldwide through objective, data-based analysis. 'The Top Ortho Practice Award is the first global program to recognize orthodontic excellence based on objective clinical data, not popularity.' Unlike traditional awards based on subjective nominations or popularity, the Top Ortho Practice Award is rooted in objective metrics derived from millions of patient scans and clinical interactions. Practices are selected based on exceptional outcomes in hygiene, compliance, and treatment effectiveness, using standardized benchmarks that reflect regional and global performance levels. The program identifies and celebrates practices that lead their territories in performance metrics derived from actual patient data, including hygiene, clinical techniques, and post-treatment stability. These practices will also serve as mentors and knowledge hubs, openly sharing their techniques, workflows, and philosophies to support peer learning and collective growth. DentalMonitoring will host its first Top Ortho Practice Exchange Event live in Las Vegas on September 18th, 2025, before the OP Summit 2025. Sign up here to register 'This initiative is about more than recognition — it's about raising the bar for what's possible in orthodontic care,' said Philippe Salah, CEO of DentalMonitoring. 'By highlighting data-backed excellence, we're helping the industry move toward more measurable, scalable impact.' Through this initiative, DentalMonitoring reaffirms its commitment to transforming orthodontics, motivating practices to unlock their full potential, and ultimately supporting them in delivering better care to patients everywhere. About DentalMonitoring DentalMonitoring sets new standards in orthodontics with its AI-powered, FDA De Novo-approved, and MDR-certified remote monitoring software. Designed for use with multiple appliances or treatment phases, it enables doctors to monitor patients remotely, enhance clinical control, and improve efficiency. Patients benefit from features like in-app messaging, convenient guided scans, and real-time feedback. With its latest innovations, DentalMonitoring helps practices optimize workflows and deliver outstanding care. With over 13,000 clinical data results, DentalMonitoring is transforming the orthodontic experience for patients and practices worldwide by connecting innovation with orthodontic needs.
Yahoo
2 hours ago
- Yahoo
DentalMonitoring Launches "Top Ortho Practice Award" to Recognize Data-Driven Excellence in Orthodontic Care
PARIS, June 20, 2025--(BUSINESS WIRE)--DentalMonitoring, the global leader in AI-powered remote monitoring for orthodontics, is proud to announce the launch of the Top Ortho Practice Award, the first-of-its-kind recognition program that celebrates top-performing orthodontic practices worldwide through objective, data-based analysis. Unlike traditional awards based on subjective nominations or popularity, the Top Ortho Practice Award is rooted in objective metrics derived from millions of patient scans and clinical interactions. Practices are selected based on exceptional outcomes in hygiene, compliance, and treatment effectiveness, using standardized benchmarks that reflect regional and global performance levels. The program identifies and celebrates practices that lead their territories in performance metrics derived from actual patient data, including hygiene, clinical techniques, and post-treatment stability. These practices will also serve as mentors and knowledge hubs, openly sharing their techniques, workflows, and philosophies to support peer learning and collective growth. DentalMonitoring will host its first Top Ortho Practice Exchange Event live in Las Vegas on September 18th, 2025, before the OP Summit 2025. Sign up here to register "This initiative is about more than recognition — it's about raising the bar for what's possible in orthodontic care," said Philippe Salah, CEO of DentalMonitoring. "By highlighting data-backed excellence, we're helping the industry move toward more measurable, scalable impact." Through this initiative, DentalMonitoring reaffirms its commitment to transforming orthodontics, motivating practices to unlock their full potential, and ultimately supporting them in delivering better care to patients everywhere. About DentalMonitoring DentalMonitoring sets new standards in orthodontics with its AI-powered, FDA De Novo-approved, and MDR-certified remote monitoring software. Designed for use with multiple appliances or treatment phases, it enables doctors to monitor patients remotely, enhance clinical control, and improve efficiency. Patients benefit from features like in-app messaging, convenient guided scans, and real-time feedback. With its latest innovations, DentalMonitoring helps practices optimize workflows and deliver outstanding care. With over 13,000 clinical data results, DentalMonitoring is transforming the orthodontic experience for patients and practices worldwide by connecting innovation with orthodontic needs. View source version on Contacts Media Contact Celine Cendras-WhiteHead of Marketing North
Business Wire
2 hours ago
- Business Wire
Archeus Technologies Receives FDA Clearance of Investigational New Drug Application for ART-101 in Development for the Treatment of Prostate Cancer
MADISON, Wis.--(BUSINESS WIRE)-- Archeus Technologies, a company developing radiopharmaceutical therapies for the treatment of patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule that Archeus has developed for the imaging and treatment of prostate cancer. This IND clearance enables Archeus to initiate a Phase 1 clinical trial in men with metastatic castration-resistant prostate cancer (mCRPC), which is expected to start later this year. ART-101 was discovered and developed by Reinier Hernandez, Ph.D., assistant professor of medical physics at the University of Wisconsin–Madison, with robust development support from the Wisconsin Alumni Research Foundation. The therapy targets prostate-specific membrane antigen (PSMA), similar to several FDA-approved imaging and therapeutic agents. However, preclinical data demonstrates that ART-101 exhibits higher tumor uptake and retention, as well as lower normal tissue and salivary gland uptake, relative to current FDA-approved PSMA-targeting agents. Archeus plans to evaluate ART-101 as a theranostic radiopharmaceutical agent with the potential to deliver alpha particle-emitting isotopes with greater efficacy and safety compared with current standards of care. 'This IND clearance marks an important milestone for Archeus as we prepare to initiate the first of multiple clinical trials set to begin this year from our broader portfolio of differentiated radiopharmaceutical assets for difficult-to-treat cancers,' said Evan Sengbusch, Ph.D., chief executive officer of Archeus Technologies. 'ART-101 represents a promising approach to targeting PSMA-positive prostate cancer with the potential to deliver meaningful clinical benefit and reduced side effects for patients. We are eager to begin evaluating ART-101 in patients to better understand its full therapeutic potential.' In addition, Archeus received IND clearances in October 2024 for its lead therapeutic candidate, ARC-706, and companion diagnostic, ARC-166. The company plans to advance the two assets - together as a theranostic pair - into clinical development this year. Archeus is developing ARC-706 for combination use with certain validated immunotherapies across a range of cancer types. Preclinical data indicate that this radiopharmaceutical agent and treatment paradigm may produce curative responses, as well as immune memory against cancers that are otherwise resistant to these immunotherapies. About Archeus Technologies Archeus Technologies is a company developing radiopharmaceutical therapies for some of the most difficult-to-treat cancers. Starting with its Phase 1-ready therapeutic candidate, ARC-706, the company has assembled a growing pipeline of differentiated radiopharmaceutical therapy agents and companion diagnostic assets with the potential to provide curative responses to patients with advanced cancer. Archeus is led by an executive team with proven radiopharmaceutical expertise and a demonstrated record of advancing innovative agents from discovery through clinical development. In addition, Archeus has a long-standing strategic collaboration with the University of Wisconsin–Madison (UW), a global leader in radiopharmaceuticals and theranostics. To learn more, visit
